OrderlyMeds LLC dba OrderlyMeds – FDA Warning Letter, Mar 1, 2026

The FDA issued a warning letter to OrderlyMeds LLC (dba OrderlyMeds) on June 8, 2026, following a review of the company"s website conducted in March 2026. The investigation focused on the marketing of compounded semaglutide and tirzepatide products. The FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act, specifically regarding false and misleading representations that result in the misbranding of drugs. The primary issues include the unauthorized use of the OrderlyMeds logo on product labels, which incorrectly suggests the company is the actual manufacturer, and the false claim that products are sourced from "FDA-licensed" or "FDA-approved" pharmacies. The FDA emphasized that it does not license or approve compounding pharmacies or their specific compounded drugs. To achieve compliance, OrderlyMeds must investigate the root causes of these violations and implement corrective measures. The company is required to provide a written response within 15 business days outlining the steps taken to correct the issues, including identifying the actual compounding entities and modifying or removing misleading website content. Failure to address these violations may result in legal actions such as product seizures or injunctions.